The Ministry of Health will include, in the Unified Health System (SUS), the combined treatment of venetoclax with azacitidine for adult patients with newly diagnosed acute myeloid leukemia. The combination of drugs is indicated for patients who, due to clinical conditions, are not eligible for standard treatment with intensive chemotherapy, being another therapy alternative for this group. Related news: Study seeks to eliminate vertical transmission of viruses that cause leukemia. Anvisa authorizes research on patients with B acute lymphocytic leukemia. Leukemia kills former Chinese president, Jian Zemim. According to Ordinance No. 30/2026, published this Monday (15), the new option will be made available in the public health network within 180 days, as provided for by the federal standard that regulates the incorporation of technologies into the SUS. The measure follows the recommendation of the National Commission for the Incorporation of Technologies into the Unified Health System (Conitec) and is aligned with the Clinical Protocol of the Ministry of Health. The technical report that supported the decision will be available for public consultation on the Conitec portal.  Leukemia According to the Ministry of Health, leukemia is a type of blood cancer originating in the bone marrow, the tissue responsible for producing red and white blood cells and platelets. When there is a genetic mutation, these components can transform into cancerous cells. In the acute form, the disease becomes even more fatal if not treated early. Diagnosis in the early stages and specialized referral are essential for good treatment results.  This is the most common form of acute leukemia in adults and mainly affects elderly patients.